Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
CSL ( (AU:CSL) ) has shared an update.
CSL Limited announced a change in the shareholding interests of its director, Ms Alison Watkins AM. The change involved the acquisition of 154 Ordinary Shares through the exercise of 154 Rights under the company’s Non-Executive Director Rights Plan. This acquisition was funded by a portion of her Board fee, reflecting an ongoing commitment to align director interests with shareholder value. Such changes in director shareholding could impact perceptions of company stability and governance among stakeholders.
More about CSL
CSL Limited is a global biotechnology company that specializes in developing and delivering innovative biopharmaceuticals. The company focuses on serving patients with rare and serious diseases by providing a range of therapies, including those for immunological and hematological conditions.
YTD Price Performance: -6.16%
Average Trading Volume: 767
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $79.32B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.
